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Norfloxacin is one of the first commercially available (and most widely used) fluoroquinolone antibiotics. 
This paper reports the development and validation of a simple, sensitive, accurate and reproducible 
turbidimetric assay method to quantify norfloxacin in tablets formulations in only 4 hours. The bioassay 
is based on the inhibitory effect of norfloxacin upon the strain of Staphylococcus epidermidis ATCC 
12228 IAL 2150 used as test microorganism. The assay was performed 3x3 parallel lines like, three tubes 
for each concentration of reference substance and three tubes for each sample concentration. The results 
were treated statistically by analysis of variance and were found to be linear (r2 = 0.9999) in the selected 
range of 25–100 μg mL-1; precise (intra-assay: relative standard deviation (RSD) = 1.33%; inter-assay: 
RSD = 0.21%), accurate (100.74%) and robust with RSD lower than 4.5%. The student’s t-test showed 
no statistically significant difference between the proposed turbidimetric method and an HPLC method 
previously validated. However the turbidimetric assay can be used as a valuable alternative methodology 
for the routine quality control of this medicine, complementary to other physical-chemical methods.
Uniterms: Microbiological assay. Quality control. Norfloxacin/quantification in tablets. Turbidimetric 
method/quality control/validation. Antimicrobials/quality control.
O norfloxacino foi a primeira fluorquinolona (e mais utilizada) disponível no mercado. Este trabalho 
divulga um novo desenvolvimento e validação de um método turbidimétrico simples, sensível, preciso 
e reprodutível para a quantificação de norfloxacino em comprimidos em apenas 4 horas. O bioensaio 
é baseado no efeito inibitório de norfloxacino sobre a cepa Staphylococcus epidermidis ATCC 12228 
IAL 2150, utilizada como micro-organismo teste. O bioensaio foi efetuado através do delineamento 
de linhas paralelas 3x3, em que três tubos foram utilizados para a solução padrão e três tubos para 
as concentrações da amostra. Os resultados foram tratados estatisticamente pela análise de variância, 
apresentando coeficiente de correlação linear de r2 = 0,9999, na faixa de 20 a 100 μg mL-1; precisão 
(intra-ensaio: desvio padrão relativo (RSD) 1,33%; inter-ensaio: RSD=0,21%), exatidão (100,74%) e 
robustez com RSD menor que 4,5%. O teste-t mostrou não haver diferença estatisticamente significativa 
entre o método turbidimétrico proposto e um método por HPLC previamente validado. No entanto, o 
ensaio turbidimétrico pode ser utilizado como método alternativo para o controle de qualidade de rotina 
para este antimicrobiano, como um complemento de outros métodos físico-químicos.
Unitermos: Ensaio microbiológico. Norfloxacino/quantificação em comprimidos. Método turbidimétrico/
controle de qualidade/validação. Antimicrobianos/controle de qualidade.
INTRODUCTION
Norfloxacin (1-ethyl-6-fluoro-1,4-dihydro-4-oxo-
7-(1-piperazinyl)-3-quinoline carboxylic acid) with 
a molecular weight of 319.33 g mol-1 (Figure 1), is a 
synthetic antibiotic from the fluoroquinolone family (Well 
et al., 1998; Lu et al., 2012). It belongs to the second 
generation of fluoroquinolones, which are characterized 
by a somewhat broader spectrum of activity against 
Gram-negative pathogens such as Escherichia coli, 
Klebsiella spp., Pseudomonas spp., Salmonella spp., and 
Campylobacter spp however Gram-positive pathogens 
such as Staphylococcus aureus, Streptococcus faecalis and 
Actinobacillus spp. are more susceptible to this drug than 
L. Chierentin, H. R. N. Salgado630
first generation quinolone members differing in a fluorine 
atom at the 6th position and a piperazine moiety at the 7th 
position (Pohlhaus, Kreuzer, 2005; Deng, Su, Kang, 2006).
The mechanism of action of norfloxacin involves 
inhibition of type II topoisomerase (DNA gyrase) which 
is essential for DNA replication and its use leads to 
double-stranded DNA break and cell death. Norfloxacin 
is widely used for the treatment of bacterial infections of 
the urinary tract, gastrointestinal tract infections and the 
respiratory tract (Cordoba, Cordoba, Bernabe, 1996; Liu 
et al., 2011). Norfloxacin has a relatively broad spectrum 
of antimicrobial activity, excellent tissue penetration and 
exerts bacterial action in low concentrations, often at a 
minimum inhibitory concentration (MIC) of less than 0.1 
μg mL-1 (Fernandes, 1988; Pavithra, Prakash, Jayakumur, 
2010).
For the determination of norfloxacin in biological 
fluids the literature reports physicochemical methods such 
as liquid chromatography (Guo et al., 2005), capillary 
electrophoresis (Liu, Jia, Tian, 2008), polarography 
(Lin, Zeping, Yuzhen, 2000) and volumetric analysis 
(Baraza, 1985; Shen, Wang, Liu, 1993; Gu et al., 1994). 
Microbiological methods for norfloxacin evaluation 
in pharmaceutical preparations were found in the 
literature (Farmacopeia Brasileira, 2001), which uses 
Staphylococcus epidermidis using an agar diffusion 
method. In previous work Froehlich and coworkers used 
Bacillus subtilis in agar diffusion method by cylinders 
and plate (Froehlich, Schapoval, 1990). An important 
advantage of turbidimetric assay is that the drug in the 
study can be dissolved to a higher extent. Traditional 
microbiological assays for antibiotics which are based 
upon the inhibition of growth of a sensitive microorganism 
require incubation times of 18-24 h (Simpson, Kobos, 
1984), therefore, the amount of time required for a 
microbiological assay can be significantly reduced by a 
turbidimetric test that requires only 4 h.
Microbiological turbidimetric assays are generally 
low cost assays and moreover, simple procedures 
of  b ioassays  have a l lowed them to  become an 
alternative methodology for drug potency assessment in 
pharmaceutical formulations. In addition, bioassay is an 
ecological technique because it is not a residue or solvent 
procedure. The aim of the present study was to develop 
and validate a simple, sensitive, precise, accurate and 
rapid microbiological assay by the turbidimetric method 
to quantify norfloxacin in tablets as a new alternative to 
the physicochemical methods described in the literature.
MATERIAL AND METHODS
Standard and reagents
Norfloxacin reference standard (purity 100%) and 
pharmaceutical product norfloxacin tablet with a label 
claim of 400 mg drug was obtained from União Química 
(Pouso Alegre, Brazil). Sodium hydroxide (NaOH) was 
obtained from Synth (São Paulo, Brazil). All reagents 
used were of the analytical grade. Eluents and reference 
substance solutions were prepared with high-quality water 
obtained from a Milli-Q system (Millipore, Milford, MA, 
USA) for the bioassay.
Norfloxacin reference substance solutions
Stock solutions were prepared by dissolving 12.5 mg 
of norfloxacin (reference substance) in 25.0 mL amber 
volumetric flask with 5 mL of 0.1 M NaOH solution, with 
30 minutes sonication. The final volume was completed 
with sterile water. Aliquots of this solution were diluted 
in sterile water to give concentrations of 25, 50 and 
100 μg mL-1 (S1, S2 and S3, respectively), which were 
used in the bioassay.
Preparation of sample solutions
Twenty tablets of norfloxacin were weighed, ground, 
and mixed. An appropriate amount (21.91 mg) was added 
to 5 mL of 0.1 M NaOH sterile solution, with 30 minutes 
sonication, the final volume was completed with water 
in a 25 mL volumetric flask. This solution was filtered 
using Whatman filter paper n°1. Aliquots of this solution 
were accordingly diluted in sterile water to obtain the 
concentrations of 25, 50 and 100 μg mL-1 (T1, T2 and T3, 
respectively) which were tested against S1, S2 and S3.
Microorganism and inoculum
The cultures of Staphylococcus epidermidis 
ATCC 12228 IAL 2150 (obtained of Instituto Adolfo 
FIGURE 1 - Chemical structure of norfloxacin (CAS 70458-
96-7).
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Lutz, São Paulo, Brazil) were cultured on brain heart 
infusion (BHI) (Acumedia-USA) at 35°C for 24 h. The 
microorganism standardization was carried out as per 
the procedure described in the Brazilian and The United 
States Pharmacopeias (ANVISA, 2010; United States 
Pharmacopeia, 2012). A diluted culture suspension 
of 25 ± 2% turbidity (transmittance) was obtained 
with the wavelength set at 580 nm, using a suitable 
spectrophotometer (Beckman Coulter, CA, USA) and a 10 
mm diameter test tube as an absorption cell against BHI 
as blank. From this standardized suspension, aliquots of 
0.6 mL were added to each tube.
Turbidimetric bioassay
Twenty glass tubes (25x145 mm) were organized 
in a rack, each tube with 10 mL of sterile BHI and 0.2 
mL each of reference substance and sample solution. 
Upon completion of the rack of test solutions, was added 
0.6 mL of inoculum was added to each tube in the rack 
and the completed rack was immediately placed in an 
incubator (32 rotation per minute; Shaker-model MA 
420, Marconi, Brazil) water bath maintained at 35°C. The 
tubes were incubated for 4 h. After incubation 0.5 mL of 
12% formaldehyde was added to each tube, taking one 
rack at time, and its absorbance was read using, a suitable 
spectrophotometer with the wavelength set at 530 nm. 
The bioassay was performed 3x3 parallel lines like, three 
tubes for each concentration of reference substance and 
three tubes for each sample concentration (S1, S2 and S3; 
T1, T2 and T3), one tube for the positive control (BHI 
and 0.6 mL of inoculum), and one tube for the negative 
control (only 10 mL of BHI). For each concentration 
of the reference substance and sample three replicates 
were made.
Calculation
To calculate the activity of norfloxacin in tablets, the 
Hewitt equation was used (Hewitt, 2004). The bioassay 
was statistically calculated by the linear parallel model and 
means of regression analysis and verified using analysis of 
variance (United States Pharmacopeia, 2012).
Method validation
The developed turbidimetric bioassay method 
was validated for the following parameters: Linearity, 
precision, accuracy, specificity, robustness and limit of 
detection (LOD) and quantitation (LOQ) (ICH, 2005; 
United States Pharmacopeia, 2012).
Linearity
The calibration curve was obtained at three 
concentration levels (25 – 100 μg mL-1) of the reference 
substance and three doses of sample. The linearity was 
evaluated by the least square regression method with 
triplicate determinations at each concentration level.
Precision
The precision of the bioassay was determined by 
repeatability (intra-assay) and intermediate precision 
(inter-assay) and was expressed as the relative standard 
deviation (RSD). Repeatability was calculated from 
six replicates of norfloxacin against the norfloxacin 
reference substance, by the same analyst, under the same 
experimental conditions on the same day (intra-assay). 
The intermediate precision was evaluated performing the 
analysis in the same laboratory on 3 days (inter-assay).
Accuracy
The recoveries were determined at three concentration 
levels (80, 100, and 120%), by adding known amounts of 
norfloxacin reference substance to the samples at the 
beginning of the process. Accurate aliquots of 0.3, 0.5, and 
0.7 mL of the reference substance solution (500 μg mL-1) 
were transferred into a 10 mL volumetric flask together with 
0.5 mL of sample solution (500 μg mL-1) and diluted with 
sterile water to give final concentrations of 40, 50, and 60 μg 
mL-1, respectively. The percentage recovery of norfloxacin 
reference substance added was calculated.
Specificity
The specificity of the development method was 
determined by means of a placebo mixture (talc, lactose, 
microcrystalline cellulose, povidone, magnesium stearate 
and sodium croscarmelose). 
Robustness
Robustness was determined by analyzing the same 
sample under a variety of conditions. The considered 
factors were incubation time and wavelength. The relative 
standard deviation (RSD) was calculated.
Limit of detection (LOD) and quantitation (LOQ)
The LOD and LOQ of norfloxacin by the proposed 
method were determined using calibration reference. LOD 
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and LOQ were calculated as 3 and 10 σ/S, respectively, 
where S is the slope of the calibration curve and σ is the 
standard deviation of y-intercept of regression equation.
High performance liquid chromatography (HPLC) 
method
An HPLC method previously developed and 
validated by our study group has been chosen as a 
comparative method for the determination norfloxacin 
solution. The mobile phase consisted of mixture of 5% 
acetic acid aqueous solution and methanol (80:20, v/v). 
This was found to give sharp peak of norfloxacin at a 
retention time of 5.7 min. HPLC analysis of norfloxacin 
was carried out at a wavelength of 277 nm with a flow rate 
1.0 mL/min, injection volume was 20 µL and an Agilent 
Zorbax® C18 analytical column (150 x 4.6 mm; 5 µm) was 
used (Chierentin, Salgado, 2013).
RESULTS AND DISCUSSION
In the turbidimetric bioassay, an experimental 3 x 3 
design, using three dose levels for each reference substance 
and sample was used following the procedure described in 
the Brazilian and United State Pharmacopoeias (Froehlich, 
Schapoval, 1990; United States Pharmacopeia, 2012; 
Farmacopeia Brasileira, 2010).
The experimental conditions were adjusted to 
accurately determine the performance of the assay. 
Some parameters were tested earlier to establish the 
conditions described and show in Table I. The strain of 
Staphylococcus epidermidis ATCC 12228 IAL 2150, 
was found to be a suitable microorganism that allowed 
quantitation of norfloxacin. The reason why we choose 
the S. epidermidis was that this microorganism is gram 
positive and less danger them others. The positive and 
negative control of the bioassay can be compared in the 
Figure 2.
The selected range of the doses (25, 50 and 
100 μg mL-1) was shown to be more appropriate for this 
assay because a good linear relationship was obtained 
between the logarithm of the dose and the response, plus 
slope of the curve. For the linearity, the experimental 
mean of absorbance for reference solutions were: 0.564 
(RSD = 2.51%) for low dose, 0.448 (RSD = 2.67%) for 
medium dose and 0.314 (RSD = 1.12%) respectively. The 
representative linear equation for norfloxacin standard and 
norfloxacin sample was y = -0.18 Ln(x) + 1.1534; y = -0.18 
Ln(x) + 1.1465, where x is Ln dose and y is absorbance. 
The coefficient of regression was r2 = 0.9999; r2 = 0.9985 
respectively.
The precision of the method was determined by 
repeatability (intra-assay) and intermediate precision on 
three different days (inter-assay) and was expressed as 
RSD (%) of a series of measurements. The result obtained 
shows means RSD of 1.33% and inter-assay precision 
shows a mean RSD 0.21% indicating good precision both 
analysis.
The accuracy of the method was evaluated at 80, 
100 and 120% of the nominal analytical concentration 
in the specified range of 25.0 – 100.0 μg mL-1. The mean 
accuracy was 100.74% and RSD was 1.55% (Table II), 
FIGURE 2 - Positive control (a) and negative control (b) of the 
bioassay.
TABLE I - Conditions tested to establish the parameters for 
turbidimetric assay of norfloxacin
Parameters Conditions
Standard curve (μg mL-1) 5, 10, 25, 50 and 100
Diluents solutions Water, buffer solution pH 6.0 and 
8.0
Microorganism Staphylococcus aureus 
ATCC 6538 IAL 1851 
Staphylococcus epidermidis 
ATCC 12228 IAL 2150 
Bacillus subtilis 
ATCC 9372 IAL 1027 
Culture media Brain heart infusion and broth 
Mueller-Hinton
Inoculum (%) 4, 6 and 10
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which confirms the ability of the method to determine the 
norfloxacin concentration with accuracy, indicating an 
agreement between the true value and the measured value. 
The specificity of the bioassay was verified with absence 
of microbial activity in excipients mixture.
The robustness study was carried out by making 
small changes in wavelength (525 and 535) and incubation 
time (3h45 and 4h15). The robustness of the method shows 
%RSD value less than 5% in both small changes (Table 
III). Robustness tests are normally applied to investigate 
the effect on either precision or accuracy. It was observed 
that there were no marked changes in the potency, which 
demonstrated that turbidimetric bioassay is robust.
LOD and LOQ values for norfloxacin were found to 
be 0.83 μg mL-1 and 2.79 μg mL-1, respectively.
Regarding the quality control of medicines, 
a validated turbidimetric microbiological assay for 
determination of norfloxacin in pharmaceutical 
formulations has not been reported yet.
Microbiological methods most commonly used to 
determine the potency of the antibiotics are the methods 
of agar diffusion and turbidimetric method (Cardoso, 
Schapoval, 2000; Bakshi, Singh, 2002; Schmidt et al., 
2009; Salgado, Lopes, Lucchesi, 2006; Cazedey, Salgado, 
2011; Aléssio, Salgado, 2012; Tótoli, Salgado, 2013; 
Pedroso, Salgado, 2014). The turbidimetric method has 
the advantage of being more sensitive and requires shorter 
analysis time compared with the agar diffusion method as 
it responds to low concentrations of antimicrobials. 
The bioassay method developed for determination of 
norfloxacin tablets in this study is linear, precise, accurate, 
specificity, robustness, LOD and LOQ. All RSD value was 
less than 5%, according with the guideline.
Comparison of methods
To our knowledge, no comparative study of HPLC 
and microbiological methods to measure norfloxacin in 
tablets has been reported previously. The data obtained by 
the analysis of NOR in tablets using the microbiological 
assay were compared with labeled amounts and with 
HPLC methods (Table VI). For this comparison, the 
Student’s t-test was performed, considering a significance 
level of 5%. Analysis of variance indicated no significant 
differences between these methods (tcalculated 1.94 < tcritical 
2.77). 
The quantification of antimicrobial components by 
methods such as HPLC, although precise, cannot provide 
a true indication of microbiological activity. Attempts to 
correlate microbiological assay results with those from 
chemical methods have proved disappointing. Moreover, 
microbiological assays continue to be an important and 
essential tool for quality control of antimicrobial agents.
CONCLUSION
From the results, it can be concluded that the 
proposed bioassay method was valid and suitable 
TABLE II - Experimental values obtained in the recovery test for norfloxacin in tablets by microbiological assay
Concentration of 
sample (μg mL-1)
Concentration of 
added standard 
(μg mL-1)
Final concentrationn 
(μg mL-1)
Concentration of 
found standard 
(μg mL-1)
Recovery (%)a
Mean percentage 
recovery ± RSD 
25.00 15.00 40.00 15.65 103.03 100.74±1.55
25.00 25.00 50.00 24.91 98.86
25.00 35.00 60.00 35.32 100.34
aEach value is the mean of 3 determinations.
TABLE III - Parameters assessing the robustness of the method microbiologically
Variable Range investigated Norfloxacin a(mg/tablet) Norfloxacina (%) RSD (%)
Incubation time (time)
3h45 
4h 
4h15
372.48 
392.12 
407.57
93.12 
98.03 
101.89
4.50
Wavelength (nm)
525 
530 
535
397.12 
380.08 
384.12
99.28 
95.08 
96.03
2.27
aMean of 3 assays with 3 tubes in each
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for quantitative determination of norfloxacin in the 
formulation studied. It is a useful analytical tool as a 
supplement for the physicochemical method. In addition, 
the turbidimetric assay can be carried out in just 4h, 
improving the time for routine analysis. Organic solvents 
are widely used in the pharmaceutical industry for many 
reasons, but with green chemistry and new technology 
the use of organic solvents is diminishing in this area. 
Therefore, this new methodology is very vital to the 
contribution of green chemistry and also to the health and 
safety of the analyst.
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